VC Roundup: Annexon, Mersana Benefit As Investors Favor Private Over Public Biotechs

During a month when only two biotechnology companies have gone public, private drug developers continue to raise hundreds of millions of dollars in venture capital.

Abstract image

Biotechnology firms that are happy to remain private while US stock market investors continue to thrash public drug developers are benefitting from the industry's ongoing venture capital boom, including Annexon Bioscience Inc., Mersana Therapeutics Inc. and six other US and EU companies.

The Nasdaq Biotechnology Index (NBI) has fallen 33.2% during the past year and only one therapeutics company has gone public...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip